July 2010

Summarized by Corey Siegel, MD

This section is eligible for 0.75 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.

• Infliximab, azathioprine, or combination therapy for Crohn's disease
  Colombel JF, Sandborn WJ, Reinisch W, et al. SONIC Study Group. N Engl J Med 2010; 362: 1383–95.
• Once-daily dosing of delayed-release oral mesalamine (400 mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis
  Sandborn WJ, Korzenik J, Lashner B, et al. Gastroenterology 2010; 138: 1286–96.
• Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: Results from the PRECiSE 4 study
  Sandborn WJ, Schreiber S, Hanauer SB, et al. Clin Gastroenterol Hepatol 2010; Epub ahead of print.
• Left-sided dysplasia progresses more rapidly than right-sided dysplasia to advanced neoplasia (AN) in patients with ulcerative colitis (UC)
  Goldstone R, Itzkowitz S, Harpaz N, Ullman T. Abstract #847h.
• Aminosalicylates, thiopurines and the risk of colorectal cancer in inflammatory bowel diseases: A case-control study nested in the CESAME cohort
  Carrat F, Seksik P, Bouvier A, et al. Abstract #255.
• Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis
  Reinisch W, Sandborn W, Hommes D, et al. Abstract #847t.
• Naltrexone therapy improves activity and promotes mucosal healing in active Crohn’s disease: A placebo-controlled trial
  Smith J, Bingaman S, Ruggiero F, et al. Abstract #646.
• Double-blind, placebo-controlled, Phase IIB trial of HMPL-004 (Andrographis Paniculata Extract) in active mild-to-moderate ulcerative colitis (UC)
  Sandborn W, Targan S, Byers V, Yan X, Tang T. Abstract #847x.

April 2010

Summarized by Sonia Freidman, MD

This section is eligible for 0.75 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.

• Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males.
  Söderlund S, Granath F, Broström O, et al.
• Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease.
  Afif W, Loftus EV Jr., Faubion WA, et al.
• Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
  Baert F, Moortgat L, van Assche G, et al.
• Fibrin glue is effective in healing perianal fistulas in patients with Crohn's disease.
  Grimaud JC, Munoz-Bongrand N, Siproudhis L, et al. Groupe d’Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID).
• Delayed-release oral mesalamine 4.8 g/day (800 mg tablet) is effective for patients with moderately active ulcerative colitis.
  Sandborn WJ, Regula J, Feagan BG, et al.

December 09

This Section is eligible for 1.0 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.

• Withdrawal of corticosteroids in inflammatory bowel disease patients after dependency periods ranging from 2 to 45 years: A proposed method
  Murphy SJ, Wang L, Anderson LA, et al.
• Efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNFs
  Allez M, Vermeire S, Mozziconacci N, et al.
• Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease
  Karmiris K, Paintaud G, Noman M, et al.

September 09

This Section is eligible for 1.0 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.

• Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: Results of a multicenter, randomized, controlled trial.
  McLeod RS, Wolff BG, Ross S, et al.
• Adalimumab for the treatment of fistulas in patients with Crohn's disease
  Colombel JF, Schwartz DA, Sandborn WJ, et al.
• Azathioprine and 6-mercaptopirine for the prevention of postoperative recurrence in Crohn's disease: A meta-analysis.
  Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al.

June 09

This Section is eligible for 1.0 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.

• Treatment of active Crohn’s Disease with MLN0002, a humanized antibody to the α4β7 integrin
  Feagan BG, Greenberg GR, Wild G, et al.
• Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis
  Miele E, Pascarella F, Giannetti E, et al.
• Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis
  van der Heide F, Dijkstra A, Weersma RK, et al.

March 09

This Section is eligible for 1.0 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.

• Infliximab prevents Crohn's disease recurrence after ileal resection
  Regueiro M, Schraut W, Baidoo L, et al.
• Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications
  Kunitake H, Hodin R, Shellito PC, et al.
• Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: A randomized, controlled study
  Bossa F, Latiano A, Rossi L, et al.

December 08

This Section is eligible for 1.0 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.

• The risk of developing Crohn's disease after an appendectomy: A meta-analysis
  Kaplan GG, Jackson T, Sands BE, et al.
• Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease
  van Limbergen J, Russell RK, Drummond HE, et al.
• Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
  Barrett JC, Hansoul S, Nicolae DL, et al.
• A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
  Sandborn WJ, Feagan BG, Fedorak RN, et al.
• Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: A controlled randomized trial
  D’Haens GR, Vermeire S, van Assche G, et al.

September 08

This Section is eligible for 1.0 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.

• Immunosuppressant medications and mortality in inflammatory bowel disease
  Lewis JD, Gelfand JM, Troxel AB, et al.
• The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease
  Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS.
• Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta analysis of placebo-controlled trials
  Peyrin-Biroulet L, Deltenre P, De Suray N, et al.
• Small-bowel imaging in Crohn's disease: A prospective,
  blinded, 4 way comparison trial
  Solem CA, Loftus Jr. EV, Fletcher JG, et al.
• Risk factors for opportunistic infections in patients with inflammatory bowel disease
  Toruner M, Loftus EV Jr., Harmsen WS, et al.

June 08

This Section is eligible for 1.0 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.

• A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch–anal anastomosis
  Fleshner P, Ippoliti A, Dubinsky M, et al.
• Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: An open randomised trial
  D’Haens G, Baert F, van Assche G, et al.
• High frequency of early colorectal cancer in inflammatory bowel disease
  Lutgens MW, Vleggaar FP, Schipper MEI, et al.
• Higher incidence of abnormal Pap smears in women with inflammatory bowel disease
  Kane S, Khatibi B, Reddy D.
• Rosiglitazone for active ulcerative colitis: A randomized placebo-controlled trial
  Lewis JD, Lichtenstein GR, Deren JJ, et al; Rosiglitazone for Ulcerative Colitis Study Group.

March 08

This Section is eligible for 1.0 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.

• A pilot study of intrastricture steroid versus placebo injection after balloon dilatation of Crohn's strictures
  East JE, Brooker JC, Rutter MD, Saunders BP.
• The incidence of arterial thromboembolic diseases in inflammatory bowel disease: A population-based study
  Bernstein CN, Wajda A, Blanchard JF.
• Gender differences in presentation and course of disease in pediatric patients with Crohn's disease.
  Gupta N, Bostrom AG, Kirschner BS, et al.
• Laparoscopy or conventional open surgery for patients with ileocolonic Crohn's disease? A prospective study
  Fichera A, Peng SL, Elisseou NM, et al.
• Mortality by medication use among patients with inflammatory bowel disease, 1996–2003
  Hutfless SM, Weng X, Lui L, et al.
• Diagnostic yield of capsule endoscopy in ulcerative colitis and inflammatory bowel disease of unclassified type (IBDU)
  Mehdizadeh S, Chen G, Enayati PJ, et al.

December 07

This Section is eligible for 1.75 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.

• Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
  Vermeire S, Noman M, Van Assche G, et al.
• Crohn's disease patients' risk–benefit preferences: Serious adverse event risks versus treatment efficacy
  Johnson FR, Özdemir S, Mansfield C, et al.
• Quantifying exposure to diagnostic medical radiation in patients with inflammatory bowel disease: Are we contributing to malignancy?
  Newnham E, Hawkes E, Surender A, et al.
• Vertebral fractures and role of low bone mineral density in Crohn's disease
  Siffledeen JS, Siminoski K, Jen H, Fedorak RN.
• Thiopurine-induced liver injury in patients with inflammatory bowel disease: A systematic review
  Gisbert JP, González-Lama Y, Maté J.
• Antibiotics in Crohn's Disease Study Group. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease
  Selby W, Pavli P, Crotty B, et al.
• Utility of magnetic resonance imaging in small bowel Crohn’s disease
  Martin DR, Lauenstein T, Sitaraman SV.

October 07

This Section is eligible for 1.0 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.

• Mucosal T-cell immunoregulation varies in early and late Crohn's disease
  Kugathasan S, Saubermann L, Smith L, et al.
• CT enterography for Crohn's disease: Accurate preoperative diagnostic imaging
  Vogel J, da Luz Moreira A, Baker M, et al.
• Mucosal healing in inflammatory bowel disease: Results for a Norwegian population-based cohort
  Frøslie KF, Jahnsen J, Moum BA, et al.
• Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial
  Targan SR, Feagan BG, Fedorak RN, et al.

August 07

This Section is eligible for 4.25 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.

• Predictors of early response to infliximab in patients with ulcerative colitis
  Ferrante F, Vermeire S, Katsanos KH, et al.
• Differentiating ulcerative colitis from Crohn’s disease in children and young adults: Report of a Working Group of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition and the Crohn’s and Colitis Foundation of America.
  Working Group of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition and the Crohn's and Colitis Foundation of America
• Predicting a change in diagnosis from ulcerative colitis to Crohn’s disease: A nested, case-control study.
  Melmed GY, Elashoff R, Chen GC, et al.
• Certolizumab pegol for the treatment of Crohn’s disease.
  Sandborn WJ, Feagan BG, Stoinov S, et al, for the PRECISE 1 Study Investigators
• Maintenance therapy with certolizumab pegol for Crohn’s disease (PRECISE 2).
  Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al, for the PRECISE 2 Study Investigators
• Adalimumab induction therapy for Crohn’s disease previously treated with infliximab: A randomized trial (GAIN).
  Sandborn WJ, Rutgeerts P, Enns R, et al.

June 07

This Section is eligible for 60 minutes of CME credit. All articles in the Section must be completed before applying for CME credit.

• Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: The CHARM trial.
  Colombel JF, Sandborn WJ, Rutgeerts P, et al.
• Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children.
  Hyams J, Crandall W, Kugathasan S, REACH Study Group, et al.
• Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients.
  Matsuoka K, Iwao Y, Mori T, et al.
• Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
  Sparrow MP, Hande SA, Friedman S, et al.